Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

PURPOSE: High-dose interferon (IFN) for 1 year (HDI) is the US Food and Drug Administration–approved adjuvant therapy for patients with high-risk melanoma. Efforts to modify IFN dose and schedule have not improved efficacy. We sought to determine whether a shorter course of biochemotherapy would be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Flaherty, Lawrence E., Othus, Megan, Atkins, Michael B., Tuthill, Ralph J., Thompson, John A., Vetto, John T., Haluska, Frank G., Pappo, Alberto S., Sosman, Jeffrey A., Redman, Bruce G., Moon, James, Ribas, Antoni, Kirkwood, John M., Sondak, Vernon K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226807/
https://ncbi.nlm.nih.gov/pubmed/25332243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.53.1590
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados